Our People » Our Network
PHARMNOVO IS A BIOPHARMA COMPANY performing research and development in collaboration with internationally leading academic and pharmaceutical scientists in their fields related to pain and pain therapy.
THE PRE-CLINICAL PHASE of the PN6047 development project is fundamentally complete and planning is now in train for regulatory toxicology testing and first in man clinical trials. The regulatory toxicology programme is being designed in collaboration with selected experts who will advise and manage the conduct and analysis of the animal testing.
Clinical input into the remaining phases of the project is clearly necessary and PharmNovo has put together a first class clinical team. The team includes; Andrew Rice, Professor of Pain Research, Imperial College, London; (link), Dr Roger Knaggs, Associate Professor in Pharmacy Practice, University of Nottingham (link), Chair of the UK Clinical Pharmacy Association pain management group) and Dr Peder Andersson, Chief Executive Officer, Biosergen.
Together with Board member Dr Anthony Ford, the team has huge experience of overseeing clinical testing of new drugs, interaction with regulatory bodies and progression to the market.
PharmNovo is very pleased to announce that we have been awarded a 2.5m EUR grant and an opportunity for up to 15m EUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.
Read moreOn May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.
Read moreThe final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.
Read moreBengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.
Read more
